Details for Patent: 9,782,402

Which drugs does patent 9,782,402 protect, and when does it expire?

Patent 9,782,402 protects SUBLOCADE and is included in one NDA.

This patent has forty patent family members in twenty-nine countries.

Summary for Patent: 9,782,402

Title:	Injectable composition comprising buprenorphine
Abstract:	The present invention is directed to a buprenorphine sustained release delivery system capable of delivering buprenorphine, a metabolite, or a prodrug thereof for a duration of about 14 days to about 3 months. The buprenorphine sustained release delivery system includes a flowable composition and a solid implant for the sustained release of buprenorphine, a metabolite, or a prodrug thereof. The implant is produced from the flowable composition. The buprenorphine sustained release delivery system provides in situ 1-month and 3-month release profiles characterized by an exceptionally high bioavailability and minimal risk of permanent tissue damage and typically no risk of muscle necrosis.
Inventor(s):	Norton; Richard L. (Fort Collins, CO), Watkins; Andrew (Fort Collins, CO), Zhou; Mingxing (Fort Collins, CO)
Assignee:	Indivior UK Limited (Berkshire, GB)
Application Number:	15/334,000
Patent Claim Types: see list of patent claims	Use; Composition; Formulation; Compound;

Drugs Protected by US Patent 9,782,402

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Indivior Inc	SUBLOCADE	buprenorphine	SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS	209819-001	Nov 30, 2017		RX	Yes	No			Y			TREATING ADDICTION WITH 100 MG OR 300 MG DOSE OF BUPRENORPHINE
Indivior Inc	SUBLOCADE	buprenorphine	SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS	209819-001	Nov 30, 2017		RX	Yes	No			Y			TREATING OPIOID ADDICTION BY ADMINISTERING BUPRENORPHINE
Indivior Inc	SUBLOCADE	buprenorphine	SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS	209819-001	Nov 30, 2017		RX	Yes	No			Y			TREATING ADDICTION BY ONCE PER MONTH ADMINISTRATION OF BUPRENORPHINE
Indivior Inc	SUBLOCADE	buprenorphine	SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS	209819-001	Nov 30, 2017		RX	Yes	No			Y			TREATING ADDICTION BY SUBCUTANEOUS INJECTION OF BUPRENORPHINE
Indivior Inc	SUBLOCADE	buprenorphine	SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS	209819-002	Nov 30, 2017		RX	Yes	Yes			Y			TREATING ADDICTION BY ONCE PER MONTH ADMINISTRATION OF BUPRENORPHINE
Indivior Inc	SUBLOCADE	buprenorphine	SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS	209819-002	Nov 30, 2017		RX	Yes	Yes			Y			TREATING ADDICTION BY SUBCUTANEOUS INJECTION OF BUPRENORPHINE
Indivior Inc	SUBLOCADE	buprenorphine	SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS	209819-002	Nov 30, 2017		RX	Yes	Yes			Y			TREATING ADDICTION WITH 100 MG OR 300 MG DOSE OF BUPRENORPHINE

International Family Members for US Patent 9,782,402

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2011263478
Brazil	112012031290
Canada	2801676
Chile	2012003462
China	103079544
Colombia	6670529
Cyprus	1120761